2020
DOI: 10.3390/jof6040300
|View full text |Cite
|
Sign up to set email alerts
|

Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?

Abstract: Paracoccidioidomycosis is a neglected disease that causes economic and social impacts, mainly affecting people of certain social segments, such as rural workers. The limitations of antifungals, such as toxicity, drug interactions, restricted routes of administration, and the reduced bioavailability in target tissues, have become evident in clinical settings. These factors, added to the fact that Paracoccidioidomycosis (PCM) therapy is a long process, lasting from months to years, emphasize the need for the res… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
12
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 16 publications
(12 citation statements)
references
References 145 publications
(181 reference statements)
0
12
0
Order By: Relevance
“…Therefore, it is necessary to search for new therapeutic alternatives that reduce treatment time and, consequently, side effects. Such new broadened approaches were the object of recent reviews [ 14 , 15 ].…”
Section: Paracoccidioides and Paracoccidioidomymentioning
confidence: 99%
“…Therefore, it is necessary to search for new therapeutic alternatives that reduce treatment time and, consequently, side effects. Such new broadened approaches were the object of recent reviews [ 14 , 15 ].…”
Section: Paracoccidioides and Paracoccidioidomymentioning
confidence: 99%
“…Sulfamethoxazole is indicated when associated with trimethoprim (an association known as cotrimoxazole). Among the advantages of this association are the low cost, good tolerance, safety for prolonged use [19], and good penetration in the central nervous system [36]. Cotrimoxazole is used in patients with mild to moderate forms of PCM and neuroparacoccidioidomycosis [36].…”
Section: Paracoccidioidomycosis: Disease Diagnosis and Treatmentmentioning
confidence: 99%
“…Among the advantages of this association are the low cost, good tolerance, safety for prolonged use [19], and good penetration in the central nervous system [36]. Cotrimoxazole is used in patients with mild to moderate forms of PCM and neuroparacoccidioidomycosis [36]. Although the side effects of itraconazole and cotrimoxazole (e.g., nausea, vomiting, and diarrhea) can make treatment difficult, overall both drugs are well tolerated by patients with PCM.…”
Section: Paracoccidioidomycosis: Disease Diagnosis and Treatmentmentioning
confidence: 99%
See 1 more Smart Citation
“…Paracoccidioidomycosis is an endemic infection in Latin America, and most cases occur in Brazil, Argentina, Colombia, Ecuador, Venezuela, and Paraguay [ 28 , 29 ]. The standard treatment for both mycoses is amphotericin B and itraconazole; however, the antibacterial cotrimoxazole (sulfamethoxazole/trimethoprim combination) is also indicated for paracoccidioidomycosis [ 30 , 31 , 32 , 33 ]. Cases related to nephrotoxicity, hepatotoxicity, and drug interactions increase considerably in these diseases, as they are considered systemic and require long treatments that can last for up to 24 months [ 26 , 31 , 33 , 34 ].…”
Section: Introductionmentioning
confidence: 99%